Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
:MDWD
MDWD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.14 - $22.51
Previous CloseN/A
Volume29.05K
Average Volume (3M)53.31K
Market Cap
$226.96M
Enterprise Value$213.62M
Total Cash (Recent Filing)$9.15M
Total Debt (Recent Filing)$6.51M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 12, 2025EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding10,807,726
10 Day Avg. Volume67,084
30 Day Avg. Volume53,307
Financial Highlights & Ratios
PEG Ratio1.23
Price to Book (P/B)7.02
Price to Sales (P/S)0.00
P/FCF Ratio-11.36
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue2.67
Enterprise Value/Gross Profit81.10
Enterprise Value/Ebitda-3.34
Forecast
1Y Price Target
$29.00Price Target Upside41.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Mediwound News
PremiumCompany Announcements
MediWound’s Earnings Call: Mixed Outlook with Promising Growth
PremiumCompany Announcements
MediWound’s Q1 2025: Strategic Progress Amid Financial Challenges
PremiumCompany Announcements
MediWound Announces Q1 2025 Results and Updates on Key Trials
Bulls Say, Bears Say
Bulls Say
Funding And Development OpportunitiesBARDA's 2025 RFP could potentially provide a windfall for MediWound if they submit a bid and are awarded the contract.
Manufacturing ExpansionManagement expects a 6-fold increase to their manufacturing capacity by expanding operations in Israel and planning a US-based manufacturing site with BARDA funding.
Product Development And Market OpportunityEscharEx is a disruptive technology in the ~$2.5B chronic wound care segment, representing a significant market opportunity.
Bears Say
Financial PerformanceMediWound reported 1Q25 results with revenue of $4.0M, below expectations of $5.0M, though this was largely due to an NIH funding delay which is expected to be back on track.
Product Launch DelaysThe launch of EscharEx in the US is delayed by one year to 3Q28 compared to prior 3Q27.
Revenue DeclineRevenue in 1Q totaled $4.0M, down from $5.0M in 1Q24 and below the Street's $5.2M.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.25% Mutual Funds
1.77% Other Institutional Investors
91.86% Public Companies and
Individual Investors
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $14.14 and its highest was $22.50 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $226.96M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is Aug 12, 2025 which is in 17 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on May 21, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.662 by $0.592.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.57.
How many shares outstanding does Mediwound have?
Mediwound has 10,807,726 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.662. Following the earnings report the stock price went down -4.696%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
Mediwound Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.00 (41.53% Upside)
$29.00 (41.53% Upside)
Blogger Sentiment
Bullish
MDWD Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 6.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 4.2%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.87%
12-Months-Change
Fundamentals
Return on Equity
-77.92%
Trailing 12-Months
Asset Growth
10.64%
Trailing 12-Months
Company Description
Mediwound
Mediwound Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapies for tissue repair and regeneration. Operating primarily in the healthcare sector, Mediwound specializes in enzymatic solutions for the treatment of burn and wound care. Their core products include NexoBrid, a topical biological product for removing eschar in adults with deep partial- and full-thickness thermal burns, and EscharEx, designed for debridement of chronic and other hard-to-heal wounds.
MDWD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for MediWound. While there are significant advancements in clinical trials and strategic collaborations, financial metrics reveal challenges with declining revenue and increased losses. However, the strong growth in NexoBrid's adoption and the strategic initiatives for EscharEx show promise for future performance.Read More>MDWD Stock 12 Month Forecast
Average Price Target
$29.00
▲(41.53%Upside)
Technical Analysis
Lineage Therap
―
Eledon Pharmaceuticals
―
Design Therapeutics
―
Ventyx Biosciences
―
Tevogen Bio Holdings
―